Abstract
Free full text
New CRISPR-Cas systems from uncultivated microbes
Associated Data
Abstract
CRISPR-Cas systems provide microbes with adaptive immunity by employing short sequences, termed spacers, that guide Cas proteins to cleave foreign DNA1,2. Class 2 CRISPR-Cas systems are streamlined versions in which a single Cas protein bound to RNA recognizes and cleaves targeted sequences3,4. The programmable nature of these minimal systems has enabled their repurposing as a versatile technology that is broadly revolutionizing biological and clinical research5. However, current CRISPR-Cas technologies are based solely on systems from isolated bacteria, leaving untapped the vast majority of enzymes from organisms that have not been cultured. Metagenomics, the sequencing of DNA extracted from natural microbial communities, provides access to the genetic material of a huge array of uncultivated organisms6,7. Here, using genome-resolved metagenomics, we identified novel CRISPR-Cas systems, including the first reported Cas9 in the archaeal domain of life. This divergent Cas9 protein was found in little-studied nanoarchaea as part of an active CRISPR-Cas system. In bacteria, we discovered two previously unknown systems, CRISPR-CasX and CRISPR-CasY, which are among the most compact systems yet identified. Notably, all required functional components were identified by metagenomics, enabling validation of robust in vivo RNA-guided DNA interference activity in E. coli. Interrogation of environmental microbial communities combined with in vivo experiments allows access to an unprecedented diversity of genomes whose content will expand the repertoire of microbe-based biotechnologies.
We sought to identify previously unknown class 2 CRISPR-Cas systems in terabase-scale metagenomic datasets from groundwater, sediment, acid mine drainage biofilms, soil, infant gut, and other microbial communities. Our analyses targeted large uncharacterized genes proximal to a CRISPR array and cas1, the universal CRISPR integrase8–10. Among the 155 million protein-coding genes analyzed, we identified the first Cas9 proteins in domain Archaea, and discovered in uncultivated bacteria two new CRISPR-Cas systems, which we refer to as CRISPR-CasX and CRISPR-CasY (Fig. 1). Both the archaeal Cas9 and CasY are encoded exclusively in the genomes of organisms from lineages with no known isolated representatives.
One of the hallmarks of CRISPR-Cas9 (type II) systems was their presumed presence only in the bacterial domain3,11. We were therefore surprised to discover Cas9 proteins encoded in genomes of the nanoarchaea ARMAN-1 (Candidatus Micrarchaeum acidiphilum ARMAN-1) and ARMAN-4 (Candidatus Parvarchaeum acidiphilum ARMAN-4)12,13 in acid-mine drainage (AMD) metagenomic datasets (Extended Data Table 1 and Extended Data Fig. 1). These findings expand the occurrence of Cas9-containing CRISPR systems to another domain of life.
The CRISPR-Cas locus in ARMAN-1 includes large CRISPR arrays adjacent to cas1, cas2, cas4 and cas9 genes. This system was found on highly similar contigs (average nucleotide identity of 99.7% outside of the CRISPR array) reconstructed independently from 16 different samples. We reconstructed numerous alternative ARMAN-1 CRISPR arrays with a largely conserved end (likely comprised of the oldest spacers) and a variable region into which many distinct spacers have been incorporated (Fig. 2a, Extended Data Fig. 2, and Supplementary Table 1). Given the polarity of the array, we predict that the ~200 bp region between the end of the Cas9 gene and the variable end of the array likely contains the leader sequence and transcriptional start site. Based on the hypervariability in spacer content, we conclude that the ARMAN-1 CRISPR-Cas9 system is active in the sampled populations. Phylogenetic analysis of Cas1 (Extended Data Fig. 3a) suggests that this archaeal CRISPR-Cas system does not clearly fall into any existing type II subtype. The presence of cas4, affiliate it with type II-B systems3,11, yet the Cas9 sequence is more similar to type II-C proteins (Extended Data Fig. 4, Supplementary Data 3). Thus, the archaeal type II system may have arisen as a fusion of type II-C and II-B systems (Extended Data Fig. 3b).
Fifty-six of the spacers of the ARMAN-1 CRISPR-Cas9 system target a 10 kbp circular sequence that encodes mostly short hypothetical proteins, and is likely an ARMAN-1 virus (Fig. 2b). Indeed, cryo-electron tomographic reconstructions often identified viral particles attached to ARMAN cells12,14. ARMAN-1 protospacers also derived from a putative transposon within the genome of ARMAN-2 (another nanoarchaeon13) and a putative mobile element in the genomes of Thermoplasmatales archaea, including that of I-plasma15 from the same ecosystem (Extended Data Fig. 5). Direct cytoplasmic “bridges” were observed between ARMAN and Thermoplasmatales cells, implying a close relationship between them12,14. The ARMAN-1 CRISPR-Cas9 may thus defend against transposon propagation between these organisms, a role that is reminiscent of piRNA-mediated defense against transposition in the eukaryotic germ line16.
Unlike the ARMAN-1 CRISPR-Cas system, the ARMAN-4 cas9 gene has only one adjacent CRISPR repeat-spacer unit and no other cas genes in its vicinity (Extended Data Fig. 6). The lack of a typical CRISPR array and cas1 points to a system with no capacity to acquire additional spacers. No target could be identified for the spacer sequence, but given the conservation of the locus in samples collected over several years, we cannot rule out it is functional as a “single-target” CRISPR-Cas system. Conservation of a single spacer may indicate that the ARMAN-4 Cas9 exerts an alternative role, such as gene regulation17 or involvement in cell-cell interactions18.
Active DNA-targeting CRISPR-Cas systems use 2 to 4 nt protospacer-adjacent motifs (PAMs) located next to target sequences for self versus non-self discrimination19,20. Examining sequences adjacent to the genomic target sequences revealed a strong ‘NGG’ PAM preference in ARMAN-1 (Fig. 2c). Cas9 also employs two separate transcripts, CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA), for RNA-guided DNA cleavage21. We identified a putative tracrRNA in the vicinity of both ARMAN-1 and ARMAN-4 CRISPR-Cas9 systems (Extended Data Fig. 7). Previously, it was suggested that type II CRISPR systems were absent in archaea due to a lack of the host factor, RNase III, responsible for crRNA-tracrRNA guide complex maturation11,22. Notably, no RNase III homologs were identified in the ARMAN-1 genome (estimated to be 95% complete) and no internal promoters are predicted for the CRISPR array23, suggesting an as-yet undetermined mechanism of guide RNA production. Biochemical experiments to test cleavage activity of ARMAN-1 and ARMAN-4 Cas9 proteins purified from both E. coli and yeast and in vivo E. coli targeting assays did not reveal any detectable activity (see Extended Data Table 2 and Extended Data Fig. 7). Given the unique physiology and ecological niche of these nanoarchaea, lack of activity may be due to a post-translational modification or a co-factor absent in the experimental expression systems.
In addition to Cas9, only three families of class 2 Cas effector proteins have been discovered and experimentally validated: Cpf1, C2c1, and C2c24,24,25. Another gene, c2c3, which was identified only on small DNA fragments, has been suggested to also encode such a protein4. We hypothesized that other distinct types of effector proteins might exist within uncultivated microbes whose genomes were reconstructed from our metagenomic datasets. Indeed, a new type of class 2 CRISPR-Cas system was found in the genomes of two bacteria recovered from groundwater and sediment samples26. This system includes Cas1, Cas2, Cas4 and an uncharacterized ~980 aa protein that we refer to as CasX. The high conservation (68% protein sequence identity, Supplementary Data 1) of this protein in two organisms belonging to different phyla, Deltaproteobacteria and Planctomycetes, suggests a recent cross-phyla transfer29. The CRISPR arrays associated with each CasX had highly similar repeats (86% identity) of 37 nt, spacers of 33–34 nt, and a putative tracrRNA between the Cas operon and the CRISPR array (Fig. 1b, Extended Data Table 1). BLAST searches revealed only weak similarity (e-value > 1×10−4) to transposases, with similarity restricted to specific regions of the CasX C-terminus. Distant homology detection and protein modeling identified a RuvC domain near the CasX C-terminal end, with organization reminiscent of that found in type V CRISPR-Cas systems (Extended Data Fig. 3c). The rest of the CasX protein (630 N-terminal amino acids) showed no detectable similarity to any known protein, suggesting this is a novel class 2 effector. The combination of tracrRNA and separate Cas1, Cas2 and Cas4 proteins is unique among type V systems, and phylogenetic analyses indicate that the Cas1 from the CRISPR-CasX system is distant from those of any other known type V (Extended Data Fig. 3a). Further, CasX is considerably smaller than any known type V proteins: 980 aa compared to a typical size of ~1,200 aa for Cpf1, C2c1 and C2c3.
To test whether CasX would be capable of RNA-guided DNA targeting analogous to Cas9 and Cpf1 proteins, we synthesized a plasmid encoding a minimal CRISPR-CasX locus including casX, a short repeat-spacer array and intervening noncoding regions. We found that when expressed in E. coli, this minimal locus blocked transformation by a plasmid bearing a target sequence identified by metagenomic analysis (Fig. 3a–c, Extended Data Fig. 8). Furthermore, interference with transformation occurred only when the spacer sequence in the mini-locus matched the protospacer sequence in the plasmid target.
To identify a PAM sequence for CasX, we repeated the transformation assay in E. coli using a plasmid containing either a 5′ or 3′ randomized sequence adjacent to the target site. This analysis revealed a stringent preference for the sequence ‘TTCN’ located 5′ of the protospacer sequence (Fig. 3d). No 3′ PAM preference was observed (Extended Data Fig. 8). Consistent with this finding, we observed that ‘TTCA’ is the sequence found upstream of the putative Deltaproteobacteria CRISPR-CasX protospacer that was identified in the environmental samples. Notably, both CRISPR-CasX loci share the same PAM sequence, in line with their high degree of protein sequence homology.
Examples of both single-RNA and dual-RNA guided systems exist among type V CRISPR loci. We used environmental RNA (metatranscriptomic) data to determine whether CasX requires a tracrRNA for DNA targeting activity. This analysis revealed a non-coding RNA transcript with sequence complementarity to the CRISPR repeat encoded between the Cas2 open reading frame and the CRISPR array (Fig. 3e). To check for expression of this non-coding RNA in E. coli expressing the CasX locus, Northern blots were conducted against this transcript in both directions (Extended Data Fig. 8). The results showed expression of a transcript of ~110 nt encoded on the same strand as the casX gene, with a more heterogeneous transcript of ~60–70 nt, suggesting that the leader sequence for the CRISPR array lies between the tracrRNA and the array. Transcriptomic mapping further suggests that the CRISPR RNA (crRNA) is processed to include ~23 nt of the repeat and 20 nt of the adjacent spacer, similar to the crRNA processing that occurs in CRISPR-Cas9 systems21,22 (Fig. 3f). To determine the dependence of CasX activity on the putative tracrRNA, we deleted this region from the minimal CRISPR-CasX locus described above, and repeated the plasmid interference assays. Deletion of the putative tracrRNA-encoding sequence from the CasX plasmid abolished robust transformation interference (Fig. 3g). This putative tracrRNA was joined with the processed crRNA using a tetraloop to form a single-guide RNA (sgRNA)21. While expression using a heterologous promoter of the crRNA alone or a shortened version of the sgRNA did not have any significant plasmid interference, expression of the full-length sgRNA conferred resistance to plasmid transformation (Fig. 3g). Together, these results establish CasX as a functional DNA-targeting, dual-RNA guided CRISPR-associated protein.
We identified another new class 2 Cas protein encoded in the genomes of certain candidate phyla radiation (CPR) bacteria6,29 (Fig. 1, Extended Data Table 1). These bacteria typically have small cell sizes, very small genomes and a limited biosynthetic capacity6,30–32, indicating they are most likely symbionts6,30–33. The ~1,200 aa Cas protein, which we named CasY, appears to be part of a minimal CRISPR-Cas system that includes Cas1 and a CRISPR array (Fig. 4a). Most of the CRISPR arrays have unusually short spacers of 17–19 nt, but one system, which lacks Cas1 (CasY.5), has longer spacers (27–29 nt). No predicted tracrRNA was detected in the vicinity of CRISPR-CasY, based on partial complementarity to the repeat sequences; however, we had insufficient metatranscriptomic data mapped to the CasY loci to detect potential tracrRNA sequences. Thus, we cannot exclude the dependence of CasY on a tracrRNA for robust interference from the available data.
The six examples of CasY proteins we identified had no significant sequence similarity to any protein in public databases. A sensitive search using profile Hidden Markov Models (HMMs)34 built from published Cas proteins3,4 indicated that four of the six CasY proteins had local similarities (e-values 4×10−11– 3×10−18) to C2c3 in the C-terminal region overlapping the RuvC domains and a small region (~45 aa) of the N-terminal region (see Extended Data Fig. 3c). The remaining two CasY proteins had no significant similarity to C2c3s, despite sharing significant sequence similarity (best Blast hits: e-values 6×10−85, 7×10−75) with the other CasY proteins (Supplementary Data 2). C2c3 proteins are putative type V Cas effectors4 that were identified on short contigs with no taxonomic affiliation, and have not been validated experimentally. Strikingly, both CRISPR-CasY and C2c3 were found next to arrays with short spacers and within loci lacking Cas2, a protein considered essential for integrating DNA into the CRISPR array9,35. It remains to be seen whether these type V systems are functional for spacer acquisition.
Given the low homology of CRISPR-CasY to any experimentally validated CRISPR loci, we wondered whether this system confers RNA-guided DNA interference, but due to the short spacer length we did not have reliable information about a possible PAM motif that might be required for such activity. To work around this, the entire CRISPR-CasY.1 locus was synthesized with a shortened CRISPR array and introduced into E. coli on a plasmid vector. These cells were then challenged in a transformation assay using a target plasmid with a sequence matching a spacer in the array and containing an adjacent randomized 5′ or 3′ region to identify a possible PAM. Analysis of transformants revealed depletion of sequences containing a 5′ TA directly adjacent to the targeted sequence (Fig. 4b). Based on the identified PAM sequence, the CasY.1 locus was overexpressed using a heterologous promoter and tested against plasmids containing single PAMs. Plasmid interference was strongest in the presence of a target containing the identified 5′ TA PAM sequence (Fig. 4c). Thus, we conclude that CRISPR-CasY has DNA interference activity.
The systems described here are some of the most compact CRISPR-Cas loci identified to date and are found exclusively in metagenomic datasets. The small number of proteins that are required for interference and their relatively short length make these systems especially valuable for the development of genome editing tools. Interestingly, some of these compact loci were identified in organisms with very small genomes. As a consequence of their small genome size, these organisms likely depend on other community members for basic metabolic requirements and thus have remained largely outside the scope of traditional cultivation-based methods. For CasX and CasY, genomic context was critical for predicting functions that would not have been evident from unassembled sequence information. Furthermore, the identification of a putative tracrRNA, as well as targeted sequences uncovered through analysis of the genome-resolved metagenomic data, guided functional testing. Importantly, we show that metagenomic discoveries related to CRISPR-Cas systems are not restricted to in silico observations, but can be introduced into an experimental setting where their activity can be analyzed. Given that virtually all environments where life exists can now be probed by metagenomic methods, we anticipate that the combined computational-experimental approach will greatly expand the diversity of known CRISPR-Cas systems, enabling new technologies for biological research and clinical applications.
METHODS
Metagenomics and metatranscriptomics
Metagenomic samples from three different sites were analyzed: (1) Acid mine drainage (AMD) samples collected between 2006 and 2010 from the Richmond Mine, Iron Mountain, California36,37 (2) Groundwater and sediment samples collected between 2007 and 2013 from the Rifle Integrated Field Research (IFRC) site, adjacent to the Colorado River near Rifle, Colorado6,26. (3) Groundwater collected in 2009 and 2014 from Crystal Geyser, a cold, CO2-driven geyser on the Colorado Plateau in Utah38.
For the AMD data, DNA extraction methods and short read sequencing were reported by Denef and Banfield (2012)36 and Miller et al. (2011)37. For the Rifle data, DNA extraction, sequencing, assembly, and genome reconstruction were described by Anantharaman et al. (2016)26 and Brown et al. (2015)6. For samples from Crystal Geyser, methods follow those described by Probst et al. (2016)38 and Emerson et al. (2016)39. Rifle metatranscriptomic data was used from the data reported by Brown et al. (2015)6.
Briefly, DNA was extracted from samples using the PowerSoil DNA Isolation Kit (MoBio Laboratories Inc., Carlsbad, CA, USA). RNA was extracted from 0.2 μm filters collected from six 2011 Rifle groundwater samples. Following RNA extraction using the Invitrogen TRIzol reagent, DNA removal was done with the Qiagen RNase-Free DNase Set and Qiagen Mini RNeasy kits, and cDNA template library was generated using the Applied Biosystems SOLiD Total RNA-Seq kit. DNA was sequenced on Illumina HiSeq2000 platform, and Metatrancriptomic cDNA on 5500XL SOLiD platform after emulsion clonal bead amplification using the SOLiD EZ Bead system (Life Technologies). For the Crystal Geyser data and reanalysis of the AMD data, sequences were assembled using IDBA-UD40. DNA and RNA (cDNA) read-mapping used to determine sequencing coverage and gene expression, respectively, was performed using Bowtie241. Open reading frames (ORFs) were predicted on assembled scaffolds using Prodigal42. Scaffolds from the Crystal Geyser dataset were binned on the basis of differential coverage abundance patterns using a combination of ABAWACA6, ABAWACA2 (https://github.com/CK7), Maxbin243, and tetranucleotide frequency using Emergent Self-Organizing Maps (ESOM)44. Genomes were manually curated using % GC content, taxonomic affiliation, and genome completeness. Scaffolding errors were corrected using ra2.py (https://github.com/christophertbrown).
CRISPR-Cas computation analyses
The assembled contigs from the various samples were scanned for known Cas proteins using Hidden Markov Model (HMMs) profiles, which were built using the HMMer suite34, based on alignments from Makarova et al. (2015)3 and Shmakov et al. (2015)4. CRISPR arrays were identified using a local version of the CrisprFinder software45. Loci that contained both Cas1 and a CRISPR array were further analyzed if one of the ten ORFs adjacent to the cas1 gene encoded for an uncharacterized protein larger than 800 aa, and no known cas interference genes were identified on the same contig. These large proteins were further analyzed as potential class 2 Cas effectors. The potential effectors were clustered to protein families based on sequence similarities using MCL46. These protein families were expanded by building HMMs representing each of these families, and using them to search the metagenomic datasets for similar Cas proteins. To compare the identified protein families to known proteins, homologs were searched using BLAST47 against NCBI’s non-redundant (nr) and metagenomic (env_nr) protein databases, as well as HMM searches against the UniProt KnowledegeBase34,48. Only proteins with no full-length hits (> 25% of the protein’s length) were considered novel proteins. Distant homology searches of the putative Cas proteins were performed using HHpred from the HH-suite49. High scoring HHpred hits were used to infer domain architecture based on comparison to solved crystal structures50,51, and secondary structure that was predicted by JPred452. Protein modeling was performed using Phyre253. The HMM database, including the newly discovered Cas proteins, is available in Supplementary Data 6.
Spacer sequences were determined from the assembled data using CrisprFinder45. CRASS54 was used to locate additional spacers in short DNA reads of the relevant samples. Spacer targets (protospacers) were then identified by BLAST47 searches (using “-task blastn-short”) against the relevant metagenomic assemblies for hits with ≤ 1 mismatch to spacers. Hits belonging to contigs that contained an associated repeat were filtered out (to avoid identifying CRISPR arrays as protospacers). Protospacer adjacent motifs (PAMs) were identified by aligning regions flanking the protospacers and visualized using WebLogo55. In cases that one spacer had multiple putative protospacers with different composition of flanking nucleotides, each distinct combination of protospacer and downstream nucleotides was taken into account for the logo calculation. RNA structures were predicted using mFold56. Average nucleotide identity was computed with the pyani Python module (https://github.com/widdowquinn/pyani), using the Mummer57 method. CRISPR array diversity was analyzed by manually aligning spacers, repeats and flanking sequences from the assembled data. Manual alignments and contig visualizations were performed with Geneious 9.1.
For the phylogenetic analyses of Cas1 and Cas9 we used proteins of the newly identified systems along with the proteins from Makarova et al. (2015)3 and Shmakov et al. (2015)4. A non-redundant set was compiled by clustering together proteins with ≥ 90% identity using CD-HIT58. Alignments were produced with MAFFT59, and maximum-likelihood phylogenies were constructed using RAxML60 with PROTGAMMALG as the substitution model and 100 bootstrap samplings. Cas1 tree were rooted using the branch leading to casposons. Trees were visualized using FigTree 1.4.1 (http://tree.bio.ed.ac.uk/software/figtree/) and iTOL v361.
Generation of heterologous plasmids
Metagenomic contigs were made into minimal CRISPR interference plasmids by removing proteins associated with acquisition for CRISPR-CasX and reducing the size of the CRISPR array for both CRISPR-CasX and CRISPR-CasY. The minimal locus was synthesized as Gblocks (Integrated DNA Technology). Native promoters were used, with the exception of the overexpression of CasY.1 and expression of the crRNA alone or sgRNA for CasX in figure 3g where the J23119 constitutive promoter was used. The minimal CRISPR loci were assembled using Gibson Assembly62 into a plasmid with a p15A origin of replication and chloramphenicol resistance gene. Detailed plasmid maps are available at the links provided in Supplementary Table 2.
PAM depletion assay
PAM depletion assays were conducted as previously described63 with modification. Plasmid libraries containing randomized PAM sequences were assembled by annealing a DNA oligonucleotide containing a target with a 7 nt randomized PAM region with a primer (Supplementary Table 2) and extended with Klenow Fragment (NEB). The double stranded DNA was digested with EcoRI and NcoI and ligated into a pUC19 backbone. The ligated library was transformed into E. coli DH5α and >108 cells were harvested and the plasmids extracted and purified. 200 ng of the pooled library was transformed into electrocompetent E. coli harboring a CRISPR locus or a control plasmid with no locus. The transformed cells were plated on selective media containing carbenicillin (100 mg L−1) and chloramphenicol (30 mg L−1) for 30 hours at 25°C. Plasmid DNA was extracted and the PAM sequence was amplified with adapters for Illumina sequencing. The 7 nt PAM region was extracted and PAM frequencies calculated for each 7 nt sequence. PAM sequences depleted above the specified threshold were used to generate a sequence logo with WebLogo55.
Plasmid Interference
Putative targets identified from metagenomic sequence analysis or PAM depletion assays were cloned into a pUC19 plasmid. 10 ng of target plasmid were transformed into electrocompetent E. coli (NEB Stable) containing the CRISPR loci plasmid. CasX.1 was used for the plasmid interference assays under control of native promoters or using a strong heterologous promoter (J23119) for sgRNA and crRNA expression. CasY.1 was put under the control of a heterologous promoter (J23119) for these assays. Cells were recovered for 2 hrs at 25°C in Super Optimal Broth (SOB) and an appropriate dilution was plated on selective media. Plates were incubated at 25°C and colony forming units were counted. All plasmid interference experiments were performed in triplicate and electrocompetent cells were prepared independently for each replicate.
Northern Blots
E. coli containing the deltaproteobacteria CasX CRISPR locus was grown to OD600=1 at 25°C in SOB media. RNA was extracted by warm phenol extraction, separated on 10% denaturing polyacrylamide gel and blotted as previously described by Zhang et al. (2013)64.
ARMAN-Cas9 protein expression and purification
Expression constructs for Cas9 from ARMAN-1 (AR1) and ARMAN-4 (AR4) were assembled from gBlocks (Integrated DNA Technologies) that were codon-optimized for E. coli. The assembled genes were cloned into a pET-based expression vector as an N-terminal His6-MBP or His6 fusion protein. Expression vectors were transformed into BL21(DE3) E. coli cells and grown in LB broth at 37°C. For protein expression, cells were induced during mid-log phase with 0.4 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) and incubated overnight at 16°C. All subsequent steps were conducted at 4°C. Cell pellets were resuspended in lysis buffer (50mM Tris-HCl pH 8, 500 mM NaCl, 1 mM TCEP, 10 mM Imidazole 0.5% Triton X-100) and supplemented with Complete protease inhibitor mixture (Roche) before lysis by sonication. Lysate was clarified by centrifugation at 15000g for 40 min and applied to Superflow Ni-NTA agarose (Qiagen) in batch. The resin was washed extensively with Wash Buffer A (50 mM Tris-HCl pH 8, 500 mM NaCl, 1mM TCEP, 10 mM Imidazole) followed by 5 column volumes of Wash Buffer B (50 mM Tris-HCl pH 8, 1M NaCl, 1 mM TCEP, 10 mM Imidazole). Protein was eluted off of Ni-NTA resin with Elution Buffer (50 mM Tris-HCl pH 8, 500 mM NaCl, 1 mM TCEP, 300 mM Imidazole). The His6-MBP tag was removed by TEV protease during overnight dialysis against Wash Buffer A. Cleaved Cas9 was removed from the affinity tag through a second Ni-NTA agarose column. The protein was dialyzed into IEX Buffer A (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 mM TCEP, 5% glycerol) before application to a 5 mL Heparin HiTrap column (GE Life Sciences). Cas9 was eluted over a linear NaCl (0.3–1.5 M) gradient. Fractions were pooled and concentrated with a 30 kDa spin concentrator (Thermo Fisher). When applicable, Cas9 was further purified via size-exclusion chromatography on a Superdex 200 pg column (GE Life Sciences) and stored in IEX Buffer A for subsequent cleavage assays. For yeast expression, AR1-Cas9 was cloned into a Gal1/10 His6-MBP TEV Ura S. cerevisiae expression vector (Addgene plasmid # 48305). The vector was transformed into a BY4741 URA3 strain and cultures were grown in CSM media at 30°C. At an OD600 of ~0.6, protein expression was induced with 2% w/v galactose and incubated overnight at 16°C. Protein purification was performed as above.
RNA in vitro transcription and oligonucleotide purification
In vitro transcription reactions were performed as previously described65 using synthetic DNA templates containing a T7 promoter sequence. All in vitro transcribed putative guide RNA sequences and target RNA or DNA were purified via denaturing PAGE. Double-stranded target RNA and DNA were hybridized in 20 mM Tris HCl pH 7.5 and 100 mM NaCl by incubation at 95°C for 1 min, followed by slow-cooling to room temperature. Hybrids were purified by native PAGE. RNA and DNA sequences used in this study are listed in Supplementary Table 2.
In vitro cleavage assays
Purified DNA and RNA oligonucleotides were radiolabeled using T4 polynucleotide kinase (NEB) and [γ-32P] ATP (Perkin-Elmer) in 1× PNK buffer for 30 min at 37°C. PNK was heat inactivated at 65°C for 20 min and free ATP was removed from the labeling reactions using illustra Microspin G-25 columns (GE Life Sciences). CrRNA and tracrRNA were mixed in equimolar quantities in 1× refolding buffer (50 mM Tris HCl pH 7.5, 300 mM NaCl, 1 mM TCEP, 5% glycerol) and incubated at 70°C for 5 min and then slow-cooled to room temperature. The reactions were supplemented to 1 mM final metal concentration and subsequently heated at 50°C for 5 min. After slow-cooling to room temperature, refolded guides were placed on ice. Unless noted for buffer or salt concentration, Cas9 was reconstituted with an equimolar amount of guide in 1× cleavage buffer (50 mM Tris HCl pH 7.5, 300 mM NaCl, 1 mM TCEP, 5% glycerol, 5 mM divalent metal) at 37°C for 10 min. Cleavage reactions were conducted in 1× cleavage buffer with a 10× excess of Cas9-guide complex over radiolabeled target at 37°C or the indicated temperature. Reactions were quenched in an equal volume of gel loading buffer supplemented with 50mM EDTA. Cleavage products were resolved on 10% denaturing PAGE and visualized by phosphorimaging.
In vivo E. coli interference assays
E. coli transformation assays for ARMAN-1 Cas9 and ARMAN-4 Cas9 were conducted as previously published66. Briefly, E. coli transformed with plasmids expressing guide RNA sequences were made electrocompetent. Cells were then transformed with 9 fmol of plasmid encoding wild-type or catalytically inactive Cas9 (dCas9). A dilution series of recovered cells was plated on LB plates with selective antibiotics. Colonies were counted after 16 hr at 37°C.
Data Availability
All the sequences reported in this study for the first time have been deposited in NCBI database under BioProject PRJNA349044. The NCBI Nucleotide database accession and coordinates of each locus are specified in Extended Data Table 1. The BioSample and Sequence Reads Archive (SRA) accessions for the ARMAN-1 spacers and protospacers are detailed in Supplementary Table 1. The HMMs used in this study are provided in Supplementary Data 6.
Extended Data
Extended Data Figure 1
Extended Data Figure 2
Extended Data Figure 3
Extended Data Figure 4
Extended Data Figure 5
Extended Data Figure 6
Extended Data Figure 7
Extended Data Figure 8
Extended Data Table 1
Taxonomic group | Cas effector | NCBI Accession | Coordinates | Repeat length | # spacers | Spacers avg. length |
---|---|---|---|---|---|---|
ARMAN-1 | Cas9 | MOEG01000017 | 1827..7130 | 36 | 271 | 34.5 |
ARMAN-4 | Cas9 | KY040241 | 11779..14900 | 36 | 1 | 36 |
Deltaproteobacteria | CasX | MGPG01000094 | 4319..9866 | 37 | 5 | 33.6 |
Planctomycetes | CasX | MHYZ01000150 | 1..5586 | 37 | 7 | 32.3 |
Candidatus Katanobacteria | CasY.1 | MOEH01000029 | 459..5716 | 26 | 14 | 17.1 |
Candidatus Vogelbacteria | CasY.2 | MOEJ01000028 | 7322..13087 | 26 | 18 | 17.3 |
Candidatus Vogelbacteria | CasY.3 | MOEK01000006 | 1..4657 | 26 | 12 | 17.3 |
Candidatus Parcubacteria | CasY.4 | KY040242 | 1..5193 | 25 | 13 | 18.4 |
Candidatus Komeilibacteria | CasY.5 | MOEI01000022 | 2802..7242 | 36 | 8 | 26 |
Candidatus Kerfeldbacteria | CasY.6 | MHKD01000036 | 11503..15366 | NA | NA | NA |
Extended Data Table 2
Protein Purification | Buffer | Salt (mM) | Metal | Guide | Target | Temperature |
---|---|---|---|---|---|---|
AR1-Cas9 #1 | Tris pH 7.5 | 300 | Mg2+ Mn2+ Zn2+ | crRNA cr:69 cr:104 cr:179 | dsDNA ssDNA DNA Bubble ssRNA dsDNA | 37 |
AR1-Cas9 #1 | Tris pH 7.5 | 100–500 | Mg2+ | cr:69 cr:104 cr:179 | dsDNA | 37 |
AR1-Cas9 #1 | Tris pH 7.5 | 300 | Mg2+ Mn2+ Zn2+ | cr:69 cr:104 cr:179 | dsDNA | 30–48 |
AR1-Cas9 #1 | MOPS: pH 6 pH 6.5 pH 7.0 pH 7.5 | 300 | Mg2+ | cr:69 cr:104 cr:179 | dsDNA | 37 |
AR1-Cas9 #1 | Citrate: pH 5 pH 5.5 pH 6 | 300 | Mg2+ | cr:69 cr:104 cr:179 | dsDNA | 37 |
AR1-Cas9 #1 | Tris pH 7.5 | 300 | Mg2+ Mn2+ Zn2+ | cr:69 cr:104 cr:179 | plasmid | 37–50 |
AR1-Cas9 #2 | Tris pH 7.5 | 300 | Mg2+ Mn2+ Zn2+ | cr:69 cr:104 cr:179 | dsDNA | 37 |
AR1-Cas9 #3 | Tris pH 7.5 | 300 | Mg2+ Mn2+ Zn2+ | cr:69 cr:104 cr:179 | dsDNA | 37 |
AR1-Cas9 #4 | Tris pH 7.5 | 300 | Mg2+ Mn2+ Zn2+ | cr:69 cr:104 cr:179 | dsDNA | 37 |
AR1-Cas9 #5 | Tris pH 7.5 | 300 | Mg2+ Mn2+ Zn2+ | cr:69 cr:104 cr:179 | dsDNA | 37 |
AR1-Cas9 #6 | Tris pH 7.5 | 300 | Mg2+ Mn2+ Zn2+ | cr:69 cr:104 cr:179 | ssDNA dsDNA | 37 |
AR4-Cas9 #1 | Tris ph7.5 | 300 | Mg2+ Mn2+ Zn2+ | sgRNA-122 | dsDNA | 37 |
AR4-Cas9 #2 | Tris ph7.5 | 300 | Mg2+ Mn2+ Zn2+ | sgRNA-122 | dsDNA | 37 |
AR4-Cas9 #3 | Tris ph7.5 | 300 | Mg2+ Mn2+ Zn2+ | sgRNA-122 | dsDNA | 37 |
AR4-Cas9 #4 | Tris ph7.5 | 300 | Mg2+ Mn2+ Zn2+ | sgRNA-122 | dsDNA | 37 |
Acknowledgments
We thank Nan Ma, Kaihong Zhou and David McGrath for technical assistance; Chris Brown, Matt Olm, Mitchell O’Connell, Janice Chen and Stephen Floor for critical reading of the manuscript and useful discussions. We thank V. Yu for gift of S. cerevisiae expression strain. D.B. was supported by a long-term EMBO fellowship, L.B.H. by a US National Science Foundation Graduate Research Fellowship, and A.J.P. by a fellowship of the German Science Foundation (DFG PR 1603/1-1). J.A.D. is an Investigator of the Howard Hughes Medical Institute. This work was supported in part by a Frontiers Science award from the Paul Allen Institute to J.A.D. and J.F.B., the National Science Foundation (MCB-1244557 to J.A.D.) and the Lawrence Berkeley National Laboratory’s Sustainable Systems Scientific Focus Area funded by the U.S. Department of Energy, (DE-AC02-05CH11231 to J.F.B.). DNA sequencing was conducted at the DOE Joint Genome Institute, a DOE Office of Science User Facility, via the Community Science Program.
Footnotes
Author Contributions
D.B., L.B.H., S.C.S., J.A.D., and J.F.B. designed the study and wrote the manuscript. A.J.P., K.A., J.F.B., B.T.C., and D.B. assembled the data and reconstructed the genomes. D.B., L.B.H., S.C.S., and J.F.B. computationally analyzed the CRISPR-Cas systems. L.B.H. and D.B. designed and executed experimental work with CRISPR-CasX and CRISPR-CasY. S.C.S. designed and executed the experimental work with ARMAN Cas9. The manuscript that was read, edited, and approved by all authors.Conflict of Interest
The Regents of the University of California have filed a provisional patent application related to the technology described in this work to the United States Patent and Trademark Office, in which D.B., L.B.H., S.C.S., J.A.D. and J.F.B. are listed as inventors.
References
Full text links
Read article at publisher's site: https://doi.org/10.1038/nature21059
Read article for free, from open access legal sources, via Unpaywall: https://europepmc.org/articles/pmc5300952?pdf=render
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Article citations
Metagenomic characterization of viruses and mobile genetic elements associated with the DPANN archaeal superphylum.
Nat Microbiol, 24 Oct 2024
Cited by: 0 articles | PMID: 39448846
Engineered Cas9 variants bypass Keap1-mediated degradation in human cells and enhance epigenome editing efficiency.
Nucleic Acids Res, 52(19):11536-11551, 01 Oct 2024
Cited by: 0 articles | PMID: 39228373 | PMCID: PMC11514467
The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders.
Nat Commun, 15(1):7259, 23 Aug 2024
Cited by: 2 articles | PMID: 39179542 | PMCID: PMC11344155
Engineering Microbial Consortia as Living Materials: Advances and Prospectives.
ACS Synth Biol, 13(9):2653-2666, 22 Aug 2024
Cited by: 0 articles | PMID: 39174016
Review
Conformational dynamics of CasX (Cas12e) in mediating DNA cleavage revealed by single-molecule FRET.
Nucleic Acids Res, 52(15):9014-9027, 01 Aug 2024
Cited by: 0 articles | PMID: 38994558 | PMCID: PMC11347132
Go to all (276) article citations
Data
Data behind the article
This data has been text mined from the article, or deposited into data resources.
BioStudies: supplemental material and supporting data
BioProject
- (1 citation) BioProject - PRJNA349044
Nucleotide Sequences (2)
- (1 citation) ENA - KY040242
- (1 citation) ENA - KY040241
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
RNA Biol, 10(5):726-737, 05 Apr 2013
Cited by: 200 articles | PMID: 23563642 | PMCID: PMC3737331
Unity among the diverse RNA-guided CRISPR-Cas interference mechanisms.
J Biol Chem, 300(6):107295, 18 Apr 2024
Cited by: 1 article | PMID: 38641067 | PMCID: PMC11127173
Review Free full text in Europe PMC
New CRISPR-Cas systems discovered.
Cell Res, 27(3):313-314, 21 Feb 2017
Cited by: 1 article | PMID: 28220773 | PMCID: PMC5339838
CRISPR-Cas: Adapting to change.
Science, 356(6333):eaal5056, 06 Apr 2017
Cited by: 193 articles | PMID: 28385959
Review
Funding
Funders who supported this work.